Unique ID issued by UMIN | UMIN000035407 |
---|---|
Receipt number | R000040345 |
Scientific Title | Effect of whole lung lavage (WLL) on exhaled nitric oxide fraction in patients with autoimmune pulmonary alveolar proteinosis (aPAP) |
Date of disclosure of the study information | 2018/12/29 |
Last modified on | 2020/08/04 22:37:27 |
Effect of whole lung lavage (WLL) on exhaled nitric oxide fraction in patients with autoimmune pulmonary alveolar proteinosis (aPAP)
Effect of WLL on exhaled nitric oxide fraction in patients with aPAP
Effect of whole lung lavage (WLL) on exhaled nitric oxide fraction in patients with autoimmune pulmonary alveolar proteinosis (aPAP)
Effect of WLL on exhaled nitric oxide fraction in patients with aPAP
Japan |
autoimmune pulmonary alveolar proteinosis
Pneumology |
Others
NO
To examine the FeNO in patients with aPAP before and after the treatment with WLL
Others
The comparison of the FeNO concentration with other paramters before and after the each lung lavage in the PAP patients.
Exploratory
Explanatory
Not applicable
The measurement of the FeNO concentration before and after the each lung lavage in the PAP patients.
The comparison of the FeNO concentration with other paramters before and after the each lung lavage in the PAP patients.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
NO
NO
Institution is not considered as adjustment factor.
NO
No need to know
1
Treatment
Maneuver |
whole lung lavage (WLL) treatment
20 | years-old | <= |
80 | years-old | >= |
Male and Female
aPAP diagnosed according to standard diagnostic criteria with positive results of anti-GM-CSF antibody
1. Diagnosed as secondary or hereditary pulmonary alveolar proteinosis
2. History of malignant disease within recent 5 years
3. Complication of cardiovascular diseases including congestive heart failure, angina pectoris, hemorrhagic tendency, etc with severe condition
4. Complication of respiratory diseases such as pulmonary infectious disease, bronchial asthma, lung fibrosis, interstitial pneumonitis, or bronchiectasis
5. History or complication of infectious diseases which require systemic administration of antibiotics, antifungal or antiviral agents within recent 2 weeks
6. Severe liver dysfunction
7. Severe renal dysfunction
8. Other patients judged to be inappropriate for the study by the attending physician
20
1st name | Toshio |
Middle name | |
Last name | Ichiwata |
Tokyo Medical University Hachioji Medical Center
Department of Respiratory Medicine
193-0998
1163 Tate-machi, Hachioji-shi, Tokyo
+81426655611
shinjit-tky@umin.ac.jp
1st name | Shinji |
Middle name | |
Last name | Teramoto |
Tokyo Medical University Hachioji Medical Center
Department of Respiratory Medicine
193-0998
1163 Tate-machi, Hachioji-shi, Tokyo
042-665-5611
shinjit-tky@umin.ac.jp
Tokyo Medical University Hachioji Medical Center
self funding
Self funding
JAPAN
Tokyo Medical University Hachioji Medical Center
1163 Tatemachi Hachioji-shi Tokyo
+81426655611
shinjit-tky@umin.ac.jp
NO
東京医科大学八王子医療センター
2018 | Year | 12 | Month | 29 | Day |
Unpublished
Enrolling by invitation
2018 | Year | 06 | Month | 01 | Day |
2019 | Year | 12 | Month | 10 | Day |
2018 | Year | 06 | Month | 10 | Day |
2020 | Year | 04 | Month | 01 | Day |
2021 | Year | 04 | Month | 01 | Day |
2021 | Year | 04 | Month | 01 | Day |
2021 | Year | 05 | Month | 01 | Day |
2018 | Year | 12 | Month | 29 | Day |
2020 | Year | 08 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040345
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |